

CURRICULUM SCIENTIFICO, DIDATTICO, e CLINICO-ASSISTENZIALE

Aggiornato a Gennaio 2022

Nome, Cognome, Titolo: *Sergio Leonardi, MD, MHS*

Posizione Attuale:

Professore Associato dal 28 Dicembre 2021. In servizio presso il Dipartimento di Medicina Molecolare dell'Università degli Studi di Pavia convenzionato con l'Unità di Terapia Intensiva Cardiologica (UTIC), Fondazione IRCCS Policlinico S.Matteo, Pavia.

Responsabile Unità Operativa di Ricerca (UOR) Cardiovascular Clinical Research Center, Fondazione IRCCS Policlinico S.Matteo, dal 28 Aprile 2021.

Iscrizione all'Albo Professionale: n° 8012 Ordine dei Medici di Pavia dal 7 Giugno 2005

Data e Luogo di Nascita: 29 Agosto 1979, Catania

Cittadinanza: Italiana

Residenza: Via Antonio Giovanni Scopoli 12, 27100, Pavia

Codice Fiscale: LNRSRG79M29C351I

Cellulare: (+39) 338 7498124

Office: (+39) 0382 501881

Assistente, Sig.ra. Daniela Civardi: (+39) 0382 503715

Fax: (+39) 0382 503161

E-mail: Sergio.Leonardi@unipv.it; S.Leonardi@smatteo.pv.it

Abilitazioni Scientifica Nazionale e Metriche Accademiche

Scopus Author ID: 36059439800

ORCID ID: <https://orcid.org/0000-0002-4800-6132>

h-index (IRIS, derivato da Scopus e Web of Science): 36

Citazioni totali: 15 433

Abilitazione Scientifica Nazionale per Professore di PRIMA Fascia, SC 06/D1, SSD MED/11. Valida per 9 anni dal 9 Novembre 2020. In possesso di 3 mediane su 3 per Commissario per ASN 2021-2023.

Ruolo in Società Scientifiche Internazionali

Presidente, Gruppo di Studio Aterosclerosi Trombosi, Biologia Vascolare	2022-2024
Fellow, European Society of Cardiology (ESC)	Dal 2014 ad oggi
Board Member, Acute Cardiovascular Care Association (ACVC)	Dal 2016 ad oggi
ACVC, Congress Programme Committe Chairman	2019-2020
ACVC, Congress Programme Committe Co-Chairman	2017-2018, 2021-2022

Attività di Formazione e Ricerca

	Sede	Periodo	Qualifica, Voto
<i>Laurea in Medicina e Chirurgia</i>	Università di Pavia	1999-2004	MD, 110/110 e lode
<i>Specializzazione in Cardiologia</i>	Università di Pavia	2004-2008	Specialista, 50/50 e lode
<i>Research Fellowship</i>	Duke Clinical Research Institute Duke University Durham, North Carolina	2009-2012	MHS degree with honor
<i>Contrattista di ricerca</i>	Direzione Scientifica Fondazione IRCCS Policlinico S.Matteo, Pavia	2012-2017	/

Attività Clinica e Assistenziale

- 28.12.2021 ad oggi: **Professore Associato**, presso il Dipartimento di Medicina Molecolare dell'Università degli Studi di Pavia, convenzionato Fondazione IRCCS Policlinico S. Matteo di Pavia-Unità di Terapia Intensiva Cardiologica (UTIC).
- 28.12.2018 ad 27.12.2021: **Ricercatore di Tipo B**, presso il Dipartimento di Medicina Molecolare dell'Università degli Studi di Pavia, convenzionato Fondazione IRCCS Policlinico S. Matteo di Pavia-Unità di Terapia Intensiva Cardiologica (UTIC).
- 18.04.2017 al 27.12.2018: **Dirigente Medico di I livello con contratto a tempo indeterminato** presso l'Unità di Terapia Intensiva Cardiologica (UTIC) della Fondazione IRCCS Policlinico S. Matteo, Pavia.
- 1.10.2013 al 17.04.2017: **Contrattista Cardiologo** con > 1000 ore annuali di attività assistenziale e mansioni equiparate al personale dirigente presso le S.C. di Cardiologia e di Terapia Intensiva Cardiologica (UTIC) della Fondazione IRCCS Policlinico S. Matteo di Pavia, comprendenti attività di guardia attiva su due S.C. ed attività di un centro Hub di riferimento provinciale per STEMI e pazienti in shock cardiogeno, compresi pazienti con grave scompenso cardiaco in lista per trapianto cardiaco.

Descrizione delle competenze cliniche e della formazione:

La mia attività clinica assistenziale è incentrata sulla gestione dei pazienti con patologie cardiovascolari acute ricoverati nel Reparto di Terapia Intensiva Cardiologica (UTIC) del Policlinico S. Matteo non solo con la responsabilità diretta dei pazienti ricoverati ma anche durante le attività di guardia attiva e consulenze presso altri Reparti. Mi occupo in particolare della gestione in acuto dei pazienti con sindromi coronariche acute che richiedono terapie antitrombotiche complesse, scompenso cardiaco acuto avanzato (in particolare la gestione di pazienti in lista d'attesa per trapianto cardiaco), ed embolia polmonare acuta nonché alla cura ambulatoriale del paziente infartuato in un ambulatorio dedicato. A Giugno 2021 ho superato con successo la parte scritta del processo di certificazione dell'*Acute Cardiovascular Care Association* (ACVC) della Società Europea di Cardiologia per cardiologo intensivista. Sono inoltre in possesso di certificazione Advanced Cardiovascular Life Support (ACLS) dell'American Heart Association rinnovata a Giugno 2021. Da oltre 4 anni sono il Referente aziendale di Qualità dell'UOC UTIC dove mi occupo in particolare di promuovere iniziative volte all'integrazione ottimale delle migliori evidenze scientifiche nella pratica clinica.

La mia tesi di specializzazione in Cardiologia, incentrata sul ruolo della risonanza magnetica cardiaca nel predire il rischio di morte improvvisa e aritmie ventricolari nei pazienti con cardiomiopatia ipertrofica (Pubblicazione#128), è stata pubblicata sulla rivista *European Heart Journal* e la mia tesi di Master in Health Sciences a Duke, che ha valutato un nuovo approccio per definire la soglia ottimale dell'infarto miocardico procedurale in pazienti con sindrome coronarica acuta è stata finalista al Northwestern Cardiovascular Young Investigators' Forum ed è stata pubblicata sulla rivista *Journal of the American College of Cardiology* (Pubblicazione#118). Al mio rientro dagli Stati Uniti ho avuto un contratto di ricerca, continuativo fino al 2017, nell'ambito di un progetto di ricerca corrente dell'IRCCS Policlinico S.Matteo avente come oggetto la creazione di un partenariato con il Duke Clinical Research Institute in cui ho contribuito a sviluppare il Cardiovascular Clinical Research Center (CCRC).

Da Aprile 2021 il CCRC è una Unità Operativa di Ricerca (UOR) della Fondazione IRCCS Policlinico S.Matteo di cui sono responsabile ed in cui lavorano 5 persone tra study coordinator e data manager. Ha l'obiettivo di promuovere il disegno di studi clinici sperimentali ed iniziative di miglioramento della qualità assistenziale del Policlinico, operare la site-based clinical research delle UOC di Cardiologia e UTIC, contribuire a formare le generazioni future di investigatori clinici, ed infine migliorare la cura dei pazienti con patologie cardiovascolari trasferendo l'evidenza scientifica alla pratica clinica.

Ruolo e Responsabilità in Studi Clinici e Coordinamento di Gruppi di Ricerca

Principal Investigator, Acute Coronary Syndrome Clinical Governance Project. Una iniziativa multicentrica di miglioramento della qualità di cura in > 5100 pazienti con sindrome coronarica acuta in Italia. Questo studio ha vinto un finanziamento competitivo di EU 120,000 come studio ESR (Externally Sponsored Research), ID ESR-16-12480, da parte di AstraZeneca e MedImmune. (ClinicalTrials.Gov ID: NCT04255537)

National Coordinator and Steering Committee Member, AUGUSTUS trial -- Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention (ClinicalTrials.Gov ID NCT02415400).

National Coordinator e Steering Committee Member, HI TECH trial -- Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (ClinicalTrials.Gov ID: NCT02587260).

Principal Investigator, Sito di Pavia, PIONEER AF PCI -- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (ClinicalTrials.Gov ID: NCT01830543).

Principal Investigator, Sito di Pavia, FOURIER OLE Study -- Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries (ClinicalTrials.Gov ID: NCT03080935)

Principal Investigator, Sito di Pavia, AEGIS-II Study – A study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (ClinicalTrials.gov Identifier: NCT03473223)

Principal Investigator, Sito di Pavia, SOLOIST AHF Study -- Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (ClinicalTrials.gov Identifier: NCT03521934).

Attività Didattica

- Docente di Cardiologia-Cardiology del Corso di Laurea in Medicina e Chirurgia (*corso di laurea in inglese “Harvey”*) dall’anno accademico 2019/2020 ad oggi in cui insegno la fisiopatologia, diagnosi, e gestione di pazienti con malattie cardiovascolari diverse tra cui sindromi coronariche acute e croniche, valvulopatie, pericarditi, e miocarditi.
- Docente di Cardiologia del Corso di Laurea in Medicina e Chirurgia (*corso di laurea in lingua italiana “Golgi”*) dall’anno accademico 2019/2020 ad oggi in cui insegno la fisiopatologia, diagnosi, e gestione di pazienti con malattie cardiovascolari diverse tra cui sindromi coronariche acute e croniche, valvulopatie, pericarditi, e miocarditi.
- Docente di Fisiopatologia Cardiovascolare per il Corso Integrato di Tecniche di Laboratorio Biomedico dell’Università di Pavia (504194 - 04413), abilitante alla professione sanitaria di Tecnico di Laboratorio Biomedico, anno accademico 2020/2021.

- Docente responsabile del modulo d'insegnamento di metodologia clinica della Scuola di Specializzazione di Malattie dell'Apparato Cardiovascolare dell'Università degli Studi di Pavia negli anni accademici dal 2015/2016, ad oggi.
 - Tale modulo comprende quattro lezioni frontali da due ore ciascuna sulle basi quantitative e metodologiche della ricerca clinica, tra cui il disegno e la conduzione di studi clinici in pazienti affetti da sindrome coronarica acuta, ed è rivolto agli specializzandi del I anno. La mia esperienza didattica comprende inoltre attività di didattica frontale aggiuntiva, sempre presso la Scuola di Specializzazione di Malattie dell'Apparato Cardiovascolare dell'Università degli Studi di Pavia, con altre lezioni, tra cui la diagnosi e la classificazione dell'infarto miocardico acuto e la gestione in pronto soccorso dei pazienti con sindrome coronarica acuta e attività di tutoraggio degli specializzandi;
- Tutoraggio degli studenti di medicina durante il periodo di tirocinio professionalizzante in Malattie dell'Apparato Cardiovascolare relatore di tre tesi sperimentali di laurea e co-relatore di 2 tesi sperimentali di laurea, nell'ambito della gestione di pazienti affetti da sindrome coronarica acuta.
- Docente del Master Universitario di I livello di Cardiologia Riabilitativa e Preventiva del Dipartimento di Sanità Pubblica, Medicina Sperimentale e Forense dell'Università degli Studi di Pavia nell'anno accademico 2016/2017;

Publicazioni Scientifiche Peer-Reviewed (137)

1. Iorio A, Lombardi CM, Specchia C, Merlo M, Nuzzi V, Ferraro I, Peveri G, Oriecua C, Pozzi A, Inciardi RM, Carubelli V, Bellasi A, Canale C, Camporotondo R, Catagnano F, Vecchia LD, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gneccchi M, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Sinagra G, Senni M, Metra M. Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study). **Am J Cardiol.** 2022 Jan 18:S0002-9149(21)01204-2. doi: 10.1016/j.amjcard.2021.11.054.
2. Patti G, D'Ascenzo F, De Filippo O, Bruno F, Leonardi S, Chieffo A, Iannaccone M, Liebetrau C, Manzano-Fernández S, Gallone G, Omedè P, Cerrato E, Kinnaird T, Conrotto F, Piroli F, Henriques JPS, Wańha W, Elia E, Dominguez-Rodriguez A, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM. Safety and efficacy of

- different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multi-center study. **Eur Heart J Qual Care Clin Outcomes**. 2022 Jan 12:qcac002. doi: 10.1093/ehjqcco/qcac002.
3. Cavender MA, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Lopes RD, Leonardi S, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators*. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. **Circ Cardiovasc Interv**. 2022 Jan;15(1):e010390. doi: 10.1161/CIRCINTERVENTIONS.120.010390.
 4. Landi A, Branca M, Andò G, Russo F, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Gragnano F, Calabrò P, Campo G, Ambrosio G, Santucci A, Varbella F, Zaro T, Heg D, Windecker S, Jüni P, Pedrazzini G, Valgimigli M; MATRIX Investigators. Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. **Eur Heart J Acute Cardiovasc Care**. 2021 Dec 18;10(10):1170-1179. doi: 10.1093/ehjacc/zuab080.
 5. Gragnano F, Jolly SS, Mehta SR, Branca M, van Klaveren D, Frigoli E, Gargiulo G, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Andò G, Esposito G, Sangiorgi GM, Biondi-Zoccai G, Heg D, Calabrò P, Windecker S, Romagnoli E, Valgimigli M. Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. **EuroIntervention**. 2021 Dec 17;17(12):e971-e980. doi: 10.4244/EIJ-D-21-00441.
 6. Baldi E, Camporotondo R, Gnechi M, Totaro R, Guida S, Costantino I, Repetto A, Savastano S, Sacchi MC, Bollato C, Giglietta F, Oltrona Visconti L, Leonardi S; STEACS-EMS study group. Barriers associated with emergency medical service activation in patients with ST-segment elevation acute coronary syndromes. **Intern Emerg Med**. 2021 Nov 26:1-10. doi: 10.1007/s11739-021-02894-7.
 7. Paris S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, Agostoni P, Canale C, Carugo S, Danzi G, Di Pasquale M, Sarullo F, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Gnechi M, Leonardi S, Merlo M, Iorio A, Giovinazzo S, Bellasi A, Zaccone G, Camporotondo R, Catagnano F, Dalla Vecchia L, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Pozzi A, Provenzale G, Specchia C, Tedino C, Guazzi M, Senni M, Metra M. Implications of atrial fibrillation on the clinical course

and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. **Europace**. 2021 Oct 9;23(10):1603-1611. doi: 10.1093/europace/euab146.

8. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong P, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. **N Engl J Med**. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749.
9. Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gneccchi M, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Senni M, Metra M, Sinagra G. The prognostic value of serial troponin measurements in patients admitted for COVID-19. **ESC Heart Fail**. 2021 Jul 8. doi: 10.1002/ehf2.13462. Online ahead of print. PMID: 34236135.
10. Krychtiuk KA, Hassager C, Leonardi S. Around the clock, around the world-reflections on 24 hours of acute cardiovascular care. **Eur Heart J**. 2021 Jun 21;ehab384. doi: 10.1093/eurheartj/ehab384. Online ahead of print. PMID: 34151946.
11. Ferlini M, Leonardi S, Mandurino Mirizzi A, Montalto C, Crimi G, Repetto A, Marinoni B, Somaschini A, Ferrario M, Klersy C, Oltrona Visconti L. Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. **J Cardiovasc Med (Hagerstown)**. 2021 Jul 1;22(7):539-545. doi: 10.2459/JCM.0000000000001174. PMID: 34076601.
12. Pagnesi M, Inciardi RM, Lombardi CM, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gneccchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zacccone G, Senni M, Metra M. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy

- multicenter study. **Int J Infect Dis.** 2021 May 28;108:270-273. doi: 10.1016/j.ijid.2021.05.056. Online ahead of print. PMID: 34052406.
13. Rognoni A, D'Ascenzo F, Solli M, Mennuni MG, Galiffa V, Rosso R, Cavallino C, Ugo F, De Filippo O, Borin A, Porto I, Fedele F, Mancone M, Sardella G, Trabattoni D, Barbero U, Moncalvo C, Verardi R, Casella G, Montalto C, Leonardi S, Azzolina D, De Ferrari GM, Patti G. Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy. **Int J Cardiol.** 2021 Jun 1;332:235-237. doi: 10.1016/j.ijcard.2021.03.046. PMID: 33766626.
 14. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, Bueno H, Lettino M, Price S, Valgimigli M, Jeppsson A. Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. **Eur Heart J Acute Cardiovasc Care.** 2021 Mar 5;10(1):83-93. doi: 10.1093/ehjacc/zuaa013.
 15. Saglietto A, D'Ascenzo F, Errigo D, Leonardi S, Dewilde WJ, Conrotto F, Omedè P, Montefusco A, Angelini F, De Filippo O, Bianco M, Gallone G, Bruno F, Zaccaro L, Giannini F, Latib A, Colombo A, Costa F, De Ferrari GM. Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. **Catheter Cardiovasc Interv.** 2021;97(4):581-588. doi: 10.1002/ccd.29192.
 16. Morici N, Marini C, Sacco A, Tavazzi G, Cipriani M, Oliva F, Rota M, De Ferrari GM, Campolo J, Frigerio G, Valente S, Leonardi S, Corrada E, Bottiroli M, Grosseto D, Cacciavillani L, Frigerio M, Pappalardo F; Altshock-2 Group. Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: Rationale and design of the randomized Altshock-2 trial. **Am Heart J.** 2021;233:39-47. doi: 10.1016/j.ahj.2020.11.017.
 17. Casula M, Fortuni F, Ferlini M, Fabris F, Oltrona Visconti L, Leonardi S. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. **Am J Cardiovasc Drugs.** 2021 Mar;21(2):231-240. doi: 10.1007/s40256-020-00436-8.
 18. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, Rocca B. Antithrombotic therapy

in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). **Eur Heart J Cardiovasc Pharmacother.** 2021 Mar 15;7(2):125-140. doi: 10.1093/ehjcvp/pvaa009.

19. Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Juni P; SIDNEY Collaboration. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. **JACC Cardiovasc Interv.** 2021 Feb 22;14(4):444-456. doi: 10.1016/j.jcin.2020.11.046. PMID: 33602441.
20. Leonardi S, Gragnano F, Carrara G, Gargiulo G, Frigoli E, Vranckx P, Di Maio D, Spedicato V, Monda E, Fimiani L, Fioretti V, Esposito F, Avvedimento M, Magliulo F, Leone A, Chianese S, Franzese M, Scalise M, Schiavo A, Mazzone P, Esposito G, Andò G, Calabrò P, Windecker S, Valgimigli M. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. **J Am Coll Cardiol.** 2021 Feb 2;77(4):375-388. doi: 10.1016/j.jacc.2020.11.046.
21. Gragnano F, Branca M, Frigoli E, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Esposito F, Franzese M, Scalise M, D'Angelo C, Scalise R, De Blasi G, Andò G, Esposito G, Calabrò P, Windecker S, Pedrazzini G, Valgimigli M; MATRIX Trial Investigators. Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. **JACC Cardiovasc Interv.** 2021 Feb 22;14(4):361-373. doi: 10.1016/j.jcin.2020.11.042.
22. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H; Document reviewers. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. **Eur Heart J Acute Cardiovasc Care.** 2021 Apr 8;10(2):224-233. doi: 10.1093/ehjacc/zuaa037. PMID: 33550362.

23. Leonardi S, Branca M, Franzone A, McFadden E, Piccolo R, Jüni P, Vranckx P, Steg PG, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Heg D, Windecker S, Valgimigli M. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. **Circ Cardiovasc Qual Outcomes**. 2021 Feb;14(2):e006581. doi: 10.1161/CIRCOUTCOMES.120.006581.
24. Demarchi A, Cornara S, Sanzo A, Savastano S, Petracci B, Vicentini A, Pontillo L, Baldi E, Frigerio L, Astuti M, Leonardi S, Ghio S, Oltrona Visconti L, Rordorf R. Incidence of Ventricular Arrhythmias and 1-Year Predictors of Mortality in Patients Treated With Implantable Cardioverter-Defibrillator Undergoing Generator Replacement. **J Am Heart Assoc**. 2021 Feb 16;10(4):e018090. doi: 10.1161/JAHA.120.018090.
25. Araiza-Garaygordobil D, Montalto C, Martinez-Amezcuca P, Cabello-Lopez A, Gopar-Nieto R, Alabrese R, Almaghraby A, Catoya-Villa S, Chacon-Diaz M, Kaufmann CC, Corbi-Pascual M, Deharo P, El-Tahlawi M, Elgohari-Abdelwahab A, Guerra F, Jarakovic M, Martinez-Gomez E, Moderato L, Montero S, Morejon-Barragan P, Mohammed Omar A, Jorge-Pérez P, Przybyło P, Selim E, Sinan UY, Stratinaki M, Tica O, Trêpa M, Uribarri A, Uzokov J, Wilk K, Czerwińska-Jelonkiewicz K, Sionis A, Gierlotka M, Leonardi S, Krychtiuk KA, Tavazzi G. Impact of the COVID-19 Pandemic on Hospitalizations for Acute Coronary Syndromes: a Multinational Study. **QJM**. 2021 Jan 24;hcab013. doi: 10.1093/qjmed/hcab013. Online ahead of print.
26. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, Bueno H, Lettino M, Price S, Valgimigli M, Jeppsson A. Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. **Eur J Cardiothorac Surg**. 2021 Apr 13;59(3):522-531. doi: 10.1093/ejcts/ezaa402. PMID: 33459337.
27. Montalto C, Ferlini M, Casula M, Mandurino-Mirizzi A, Costa F, Leonardi S, Oltrona Visconti L. DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients. **Thromb Haemost**. 2021 May;121(5):687-689. doi: 10.1055/s-0040-1721145. PMID: 33212543.
28. Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, Gneccchi M, Guazzi M, Iorio A, La Rovere MT,

- Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, Metra M. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. **Clin Res Cardiol**. 2021 Jul;110(7):1020-1028. doi: 10.1007/s00392-020-01766-y. Epub 2020 Nov 3. PMID: 33141251.
29. Casula M, Fortuni F, Fabris F, Leonardi S, Gneccchi M, Sanzo A, Greco A, Rordorf R. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis. **J Cardiovasc Med (Hagerstown)**. 2020 Aug;21(8):570-576. doi: 10.2459/JCM.0000000000001041.
30. Gneccchi M, Moretti F, Bassi EM, Leonardi S, Totaro R, Perotti L, Zuccaro V, Perlini S, Preda L, Baldanti F, Bruno R, Visconti LO. Myocarditis in a 16-year-old boy positive for SARS-CoV-2. **Lancet**. 2020 Jun 27;395(10242):e116. doi: 10.1016/S0140-6736(20)31307-6.
31. Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, Camporotondo R, Catagnano F, Dalla Vecchia LA, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Nuzzi V, Oriecuia C, Peveri G, Pozzi A, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gneccchi M, Leonardi S, Merlo M, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Sinagra G, Volterrani M, Specchia C, Metra M, Senni M. Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. **JAMA Cardiol**. 2020 Nov 1;5(11):1274-1280. doi: 10.1001/jamacardio.2020.3538.
32. Ameri P, Inciardi RM, Di Pasquale M, Agostoni P, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Danzi G, Dalla Vecchia L, Giovinazzo S, Gneccchi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Provenzale G, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Lombardi CM, Senni M, Metra M. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. **Clin Res Cardiol**. 2020 Nov 3:1-9. doi: 10.1007/s00392-020-01766-y. Online ahead of print.
33. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gneccchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, Mapelli M,

- Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. **Eur J Heart Fail**. 2020 Dec;22(12):2238-2247. doi: 10.1002/ejhf.2052.
34. Leonardi S, Montalto C, Casella G, Grosseto D, Repetto A, Portolan M, Fortuni F, Ottani F, Galvani M, Cardelli LS, De Servi S, Rubboli A, De Ferrari GM, Oltrona Visconti L, Campo G. Clinical governance programme in patients with acute coronary syndrome: design and methodology of a quality improvement initiative. **Open Heart**. 2020 Dec;7(2):e001415. doi: 10.1136/openhrt-2020-001415.
35. Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Hamm C, Steg PG, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M; Collaborators. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. **EuroIntervention**. 2020 Jun 2:EIJ-D-20-00145. doi: 10.4244/EIJ-D-20-00145. Online ahead of print.
36. Katz JN, Sinha SS, Alviar CL, Dudzinski DM, Gage A, Brusca SB, Flanagan MC, Welch T, Geller BJ, Miller PE, Leonardi S, Bohula EA, Price S, Chaudhry SP, Metkus TS, O'Brien CG, Sionis A, Barnett CF, Jentzer JC, Solomon MA, Morrow DA, van Diepen S. COVID-19 and Disruptive Modifications to Cardiac Critical Care Delivery: JACC Review Topic of the Week. **J Am Coll Cardiol**. 2020 Jul 7;76(1):72-84. doi: 10.1016/j.jacc.2020.04.029.
37. Gargiulo G, Valgimigli M, Sunnåker M, Vranckx P, Frigoli E, Leonardi S, Spirito A, Gragnano F, Manavifar N, Galea R, De Caterina AR, Calabrò P, Esposito G, Windecker S, Hunziker L. Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. **Rev Esp Cardiol (Engl Ed)**. 2020 Mar 6:S1885-5857(20)30034-7. doi: 10.1016/j.rec.2020.01.005. Online ahead of print.
38. Ditali V, Carrozzi C, Leonardi S. [Short dual antiplatelet therapy: how, when and why]. **G Ital Cardiol (Rome)**. 2020 Feb;21(2 Suppl 1):14S-25S. doi: 10.1714/3311.32817.
39. Sirico D, Morici N, Soriano F, Marianeschi SM, Pedrazzini G, Leonardi S, Vignati G. Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction. **Platelets**. 2020 Feb 23:1-4. doi: 10.1080/09537104.2020.1732323. Online ahead of print.

40. Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, Rocca B. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). **Eur Heart J Cardiovasc Pharmacother**. 2020 Feb 12;pvaa009. doi: 10.1093/ehjcvp/pvaa009. Online ahead of print.
41. De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED; TECOS Study Group. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. **Am Heart J**. 2020 Feb;220:82-88. doi: 10.1016/j.ahj.2019.11.005.
42. Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Tebaldi M, Cirillo P, Hunziker L, Vranckx P, Leonardi S, Heg D, Windecker S, Valgimigli M. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. **Circulation**. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928.
43. Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. **Eur Heart J Cardiovasc Pharmacother**. 2020 Sep 17;pvaa106. doi: 10.1093/ehjcvp/pvaa106.
44. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, Valgimigli M, Mehran R, Alexander JH. Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. **Circulation**. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584.

45. Marino M, Leonardi S, Crimi G, Ferrario M, Musumeci G, Tarantini G, Lettieri C, Bettari L, Maddalena L, De Luca L, Varbella F, De Servi S. Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization : Analysis from the Apache study. **Heart Vessels**. 2020 Jan;35(1):30-37. doi: 10.1007/s00380-019-01459-1.
46. Morici N, Nava S, Sacco A, Viola G, Oreglia J, Meani P, Oliva F, Ranucci M, Leonardi S, Rossini R. Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor? **Platelets**. 2020;31(1):120-123. doi: 10.1080/09537104.
47. Fortuni F, Angelini F, Abete R, Raineri C, Sclesi L, Turco A, Crimi G, Leonardi S, Ghio S, Oltrona Visconti L, De Ferrari GM. The prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy: An updated meta-analysis. **Eur J Prev Cardiol**. 2020 Nov;27(17):1902-1905. doi: 10.1177/2047487319874352.
48. Leonardi S, Krychtiuk KA. The future for the Acute Cardiovascular Care Congress we shall find together. **Eur Heart J**. 2020 Nov 1;41(41):3979-3981. doi: 10.1093/eurheartj/ehaa491.
49. Angelini F, Fortuni F, Tsivgoulis G, Agnelli G, Bocchino PP, Franchin L, De Filippo O, Bellettini M, D'Ascenzo F, Crimi G, Leonardi S, De Ferrari GM, Paciaroni M. Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. **Cardiovasc Drugs Ther**. 2020 Sep 12. doi: 10.1007/s10557-020-07068-9.
50. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. **J Am Coll Cardiol**. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038.
51. Fortuni F, Crimi G, Angelini F, Leonardi S, D'Ascenzo F, Ferlini M, Rolando M, Raisaro A, Oltrona Visconti L, Ferrario M, Gnechi M, De Ferrari GM. Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. **Can J Cardiol**. 2019 Aug;35(8):1047-1057. doi: 10.1016/j.cjca.2019.03.006. Review.

52. De Servi S, Olivari Z, Crimi G, Marino M, Alberti LP, Tagliabue E, Leonardi S. Percutaneous coronary interventions for stable ischemic heart disease in Italy. **J Cardiovasc Med (Hagerstown)**. 2019;20(11):762-767. doi: 10.2459/JCM.0000000000000835.
53. Olivier CB, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW; CHAMPION PHOENIX Investigators * . Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. **Circ Cardiovasc Interv**. 2019 Jul;12(7):e007342. doi: 10.1161/CIRCINTERVENTIONS.118.007342.
54. Krychtiuk KA, Huber K, Leonardi S. Acute Cardiovascular Care 2019. **Eur Heart J**. 2019 Jun 21;40(24):1903-1906. doi: 10.1093/eurheartj/ehz399
55. Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). **BMJ Open**. 2019 Mar 9;9(3):e026053. doi: 10.1136/bmjopen-2018-026053.
56. Gargiulo G, Carrara G, Frigoli E, Leonardi S, Vranckx P, Campo G, Varbella F, Calabrò P, Zaro T, Bartolini D, Briguori C, Andò G, Ferrario M, Limbruno U, Colangelo S, Sganzerla P, Russo F, Nazzaro MS, Esposito G, Ferrante G, Santarelli A, Sardella G, Windecker S, Valgimigli M. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. **J Am Coll Cardiol**. 2019 Feb 26;73(7):758-774. doi: 10.1016/j.jacc.2018.12.023.
57. Fortuni F, Crimi G, Gritti V, Mirizzi AM, Leonardi S, Ferrari GM. *Primum non nocere*: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. **Eur J Prev Cardiol**. 2019 Oct;26(15):1677-1679. doi: 10.1177/2047487319826439
58. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Juni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iñiguez A, Colombo A, Alasnag M, Mullanari A, James S, Stankovic G, Ong PJJ, Rodriguez AE, Mahfoud

- F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnåker M, Valgimigli M. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. **Am Heart J.** **2019** Mar;209:97-105. doi: 10.1016/j.ahj.2018.10.009.
59. Rothenbühler M, Valgimigli M, Odutayo A, Frigoli E, Leonardi S, Vranckx P, Turturo M, Moretti L, Amico F, Uguccioni L, Contarini M, Gómez-Hospital JA, Mainar V, Creaco M, Petronio AS, Cremonesi A, Tamburino C, Fresco C, Bonmassari R, Díaz Fernández JF, Romagnoli E, Beyersmann J, Heg D, Jüni P. Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. **Eur Heart J.** **2019** Apr 14;40(15):1226-1232. doi: 10.1093/eurheartj/ehy860.
60. Leonardi S, Bhatt DL. Practical considerations for cangrelor use in patients with acute coronary syndromes. **Eur Heart J Acute Cardiovasc Care.** **2019** Feb;8(1):39-44. doi: 10.1177/2048872617707960.
61. Fortuni F, Ferlini M, Leonardi S, Angelini F, Crimi G, Somaschini A, Cornara S, Potenza A, De Servi S, Oltrona Visconti L, De Ferrari GM. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis. **Int J Cardiol** **2018** Dec 15;273:80-87. doi: 10.1016/j.ijcard.2018.08.019.
62. Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P; MATRIX Investigators. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. **Lancet.** **2018** Sep 8;392(10150):835-848. doi: 10.1016/S0140-6736(18)31714-8. Epub 2018 Aug 25. PMID: 3015398
63. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Wallentin L. Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. **J Am Coll Cardiol** **2018** Jul 3;72(1):125-126. doi: 10.1016/j.jacc.2018.04.045.
64. Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR Jr, Harrington RA, Mahaffey KW; CHAMPION

- PLATFORM and CHAMPION PCI Investigators. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. **Int J Cardiol** 2018. Nov 1;270:96-101. doi: 10.1016/j.ijcard.2018.06.034
65. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. **Circulation** 2018. Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
66. Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. **JACC Cardiovasc Interv** 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022.
67. Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. **JACC Cardiovasc Interv** 2018;11(9):856-864. doi: 10.1016/j.jcin.2018.02.006.
68. Fortuni F, Crimi G, Leonardi S, Angelini F, Raisaro A, Lanzarini LF, Oltrona Visconti L, Ferrario M, De Ferrari GM. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events. **J Cardiovasc Med (Hagerstown)** 2018;19(7):373-381. doi: 10.2459/JCM.0000000000000648.
69. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens GN, Ortega-Paz L, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators. Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. **J Am Coll Cardiol** 2018 Mar 20;71(11):1289-1291. doi: 10.1016/j.jacc.2018.01.027.
70. Gargiulo G, Carrara G, Frigoli E, Vranckx P, Leonardi S, Ciociano N, Campo G, Varbella F, Calabrò P, Garducci S, Iannone A, Briguori C, Andò G, Crimi G, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Zavalloni D, Santarelli A, Sardella G, Tresoldi S, de Cesare N, Sciahbasi A, Zingarelli A, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Valgimigli M.

Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. **J Am Coll Cardiol** 2018;71(11):1231-1242. doi: 10.1016/j.jacc.2018.01.033.

71. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA, Saia F, Valgimigli M, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society of Interventional Cardiology (SICI-GISE); Italian Society for the Study of Haemostasis and Thrombosis (SISSET); Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI); Italian Society of Surgery (SIC); Italian Society for Cardiac Surgery (SICCH); Italian Society of Vascular and Endovascular Surgery (SICVE); Italian Society of Urology (SIU); Italian Orthopaedic Society (SIOT); Italian Society of Thoracic Surgeons (SICT); Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD); Italian Society of Digestive Endoscopy (SIED); Italian Association of Hospital Gastroenterology and Digestive Endoscopy (AIGO); Italian Association of Gastroenterology and Digestive Endoscopy (SIGE); Italian Society of Maxillofacial Surgery (SICMF); Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE); Italian Society of Gynecology and Obstetrics (SIGO); Italian Society of Neurosurgery (SINch); Italian Association of Hospital Pulmonologist (AIPO); Italian Society of Periodontology (SIpP); Italian Society of Ophthalmology (SOI); Italian Association of Hospital Otorhinolaryngologist (AOOD); Italian Association of Hospital Surgeons (ACOI); Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. **JACC Cardiovasc Interv** 2018;11(5):417-434. doi: 10.1016/j.jcin.2017.10.051.
72. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L; ARISTOTLE Committees and Investigators. Digoxin and Mortality in Patients With Atrial Fibrillation. **J Am Coll Cardiol** 2018 Mar 13;71(10):1063-1074. doi: 10.1016/j.jacc.2017.12.060.
73. Leonardi S, Bueno H, Ahrens I, Hassager C, Bonnefoy E, Lettino M. Optimised care of elderly patients with acute coronary syndrome. **Eur Heart J Acute Cardiovasc Care** 2018;7(3):287-295. doi: 10.1177/2048872618761621.
74. Mandurino-Mirizzi A, Crimi G, Raineri C, Pica S, Ruffinazzi M, Gianni U, Repetto A, Ferlini M, Marinoni B, Leonardi S, De Servi S, Oltrona Visconti L, De Ferrari GM, Ferrario M. Elevated serum uric acid affects

- myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. **J Cardiovasc Med (Hagerstown)** **2018**;19(5):240-246. doi: 10.2459/JCM.0000000000000634.
75. Guimarães PO, Leonardi S, Huang Z, Wallentin L, de Werf FV, Aylward PE, Held C, Harrington RA, Moliterno DJ, Armstrong PW, White HD, Alexander KP, Lopes RD, Mahaffey KW, Tricoci P. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. **Am Heart J** **2018**;196:28-35. doi: 10.1016/j.ahj.2017.10.007.
76. Fortuni F, Ferlini M, Leonardi S. Parenteral antithrombotic therapy during primary percutaneous coronary intervention. **Minerva Cardioangiol** **2018**;66(4):411-421. doi: 10.23736/S0026-4725.18.04619-4.
77. Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano N, Tumscitz C, Tomassini F, Calabrò P, Garducci S, Crimi G, Andò G, Ferrario M, Limbruno U, Cortese B, Sganzerla P, Lupi A, Russo F, Garbo R, Ausiello A, Zavalloni D, Sardella G, Esposito G, Santarelli A, Tresoldi S, Nazzaro MS, Zingarelli A, Petronio AS, Windecker S, da Costa BR, Valgimigli M. Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. **JACC Cardiovasc Interv** **2018**;11(1):36-50. doi: 10.1016/j.jcin.2017.09.014.
78. Crimi G, Gritti V, Galiffa VA, Scotti V, Leonardi S, Ferrario M, Ferlini M, De Ferrari GM, Oltrona Visconti L, Klersy C. Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis. **J Interv Cardiol** **2018**;31(3):319-329. doi: 10.1111/joic.12473.
79. Vaduganathan M, Harrington RA, Stone GW, Steg G, Gibson CM, Hamm CW, Price MJ, Lopes RD, Leonardi S, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. **EuroIntervention** **2018**;13(15):e1841-e1849. doi: 10.4244/EIJ-D-17-00723.
80. Leonardi S, Marino M, Crimi G, Maiorana F, Rizzotti D, Lettieri C, Bettari L, Zuccari M, Sganzerla P, Tresoldi S, Adamo M, Ghiringhelli S, Sponzilli C, Pasquetto G, Pavei A, Pedon L, Bassan L, Bollati M, Camisasca P,

- Trabattoni D, Brancati M, Poli A, Panciroli C, Lettino M, Tarelli G, Tarantini G, De Luca L, Varbella F, Musumeci G, De Servi S. APpropriAteness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. **BMJ Open** [London, England] **2017 Sep 5**;7(9):e016909. doi: 10.1136/bmjopen-2017-016909.
81. Ukena C, Leonardi S, Palmerini T, Lansky A, Montalescot G, Valgimigli M. Will PIONEER AF-PCI change my practice? **EuroIntervention** **2017**;13(5):e609-e612. doi: 10.4244/EIJV13I5A95.
82. De Luca L, Musumeci G, Leonardi S, Gonzini L, Cavallini C, Calabrò P, Mauro C, Cacciavillani L, Savonitto S, De Servi S; EYESHOT Investigators. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry. **J Cardiovasc Med (Hagerstown)** **2017**;18(8):580-589. doi: 10.2459/JCM.0000000000000533.
83. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rexhaj E, Janssens G, Ortega-Paz L, Rizzotti D, van den Berge JC, Heg D, Francolini G, Windecker S, Valgimigli M; HI-TECH Investigators. Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. **Am Heart J** **2017**; 189:128-136. doi: 10.1016/j.ahj.2017.03.017.
84. Lettino M, Leonardi S, De Maria E, Halvorsen S. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. **Eur J Prev Cardiol** **2017**;24(3_suppl):61-70. doi: 10.1177/2047487317707854.
85. Leonardi S, Bhatt DL. Practical considerations for cangrelor use in patients with acute coronary syndromes. **Eur Heart J Acute Cardiovasc Care** **2017** 2019 Feb;8(1):39-44. doi: 10.1177/2048872617707960.
86. Andò G, Cortese B, Russo F, Rothenbühler M, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Jüni P, Valgimigli M; MATRIX Investigators. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. **J Am Coll Cardiol** **2017**: S0735-1097(17)36897-3. doi: 10.1016/j.jacc.2017.02.070.

87. Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). **Circ Cardiovasc Interv** 2017;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.004368.
88. Marino M, Crimi G, Leonardi S, Ferlini M, Repetto A, Camporotondo R, Demarchi A, De Pascali I, Falcinella F, Oltrona Visconti L, De Servi S, Ferrario M, De Ferrari GM, Gneccchi M. Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion-Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. **Am J Cardiol** 2017 15;119(4):508-514. doi: 10.1016/j.amjcard.2016.10.040.
89. Mandurino-Mirizzi A, Leonardi S, Melloni C. Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes. **Minerva Endocrinol** 2017;42(3):228-237. doi: 10.23736/S0391-1977.16.02571-2.
90. Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavalloni-Parenti D, Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M; MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. **BMJ** 2016 Sep 27;354:i4935. doi: 10.1136/bmj.i4935.
91. Leonardi S, Lopes RD, Steg PG, Abnoui F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. **Eur Heart J Acute Cardiovasc Care** 2018 Mar;7(2):158-165. doi: 10.1177/2048872616661692.
92. Åkerblom A, Clare RM, Lokhnygina Y, Wallentin L, Held C, Van de Werf F, Moliterno DJ, Patel UD, Leonardi S, Armstrong PW, Harrington RA, White HD, Aylward PE, Mahaffey KW, Tricoci P. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. **Am Heart J** 2016;178:1-8. doi: 10.1016/j.ahj.2016.04.013.

93. Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). **Circulation** **2016**;134(10):723-33. doi: 10.1161/CIRCULATIONAHA.115.020829
94. Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Predicting Spontaneous Myocardial Infarction for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Managed Medically: Insights from the TRILOGY ACS Trial. **J Am Coll Cardiol** **2016**;67(11):1289-97. doi: 10.1016/j.jacc.2016.01.034.
95. Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, Valgimigli M. Role of stent type and of duration of dual antiplatelet therapy in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions. Is bare metal stent implantation still a justifiable choice? A Post-hoc Analysis of the All Comers PRODIGY Trial. **Int J Cardiol** **2016**;212:110-7. doi: 10.1016/j.ijcard.2016.03.033.
96. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, Valgimigli M. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. **Am Heart J** **2016**;174:95-102. doi: 10.1016/j.ahj.2016.01.015.
97. Ferlini M, De Ferrari GM, Moroni G, Roversi P, Potenza A, Leonardi S, Repetto A, Camporotondo R, Alessandrino G, Gnechi M, Marinoni B, Guerci M, Crimi G, Ferrario M, Bressan MA, Raimondi M, De Servi S, Visconti LO. Strategies for reducing door to balloon time in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: the Pavia experience. **G Ital Cardiol (Rome)** **2016**;17(1):51-7. doi: 10.1714/2140.23192.
98. De Luca L, Leonardi S, Smecca IM, Formigli D, Lucci D, Gonzini L, Tuccillo B, Olivari Z, Gulizia MM, Bovenzi FM, De Servi S; EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. **Eur Heart J Cardiovasc Pharmacother** **2015**;1(3):168-78. doi: 10.1093/ehjcvp/pvv006.

99. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S, Garcia-Garcia H, Vranckx P, Valgimigli M. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. **EuroIntervention** **2016 Feb**;11(11):e1222-30. doi: 10.4244/EIJY15M08_04.
100. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, De Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. **N Engl J Med** **2015 Sep 10**;373(11):997-1009. doi: 10.1056/NEJMoa1507854.
101. Tricoci P, Leonardi S. Determining myocardial infarction after PCI: CK-MB, troponin, both, or neither? **MLO Med Lab Obs** **2015**;47(1):14, 16. PMID: 26281113.
102. Bagai A, Huang Z, Lokhnygina Y, Harrington RA, Armstrong PW, Strony J, White HD, Leonardi S, Held C, Van de Werf F, Wallentin L, Tricoci P, Mahaffey KW. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. **Circ Cardiovasc Interv** **2015**;8(6):e002314. doi: 10.1161/CIRCINTERVENTIONS.115.002314.
103. Adamo M, Costa F, Vranckx P, Leonardi S, Navarese EP, Garcia-Garcia HM, Valgimigli M. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. **Int J Cardiol** **2015**;190:242-5. doi: 10.1016/j.ijcard.2015.04.159.
104. De Luca L, Leonardi S, Tubaro M, Gonzini L, Lucci D, Trimarco B, Misuraca G, Ledda A, Gulizia MM, De Servi S; EYESHOT Investigators. Is the use of risk scores an indicator of guideline adherence for patients with acute coronary syndromes? Insights from the EYESHOT Registry. **Int J Cardiol** **2015**;187:80-3. doi: 10.1016/j.ijcard.2015.03.343.
105. Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). **Am J Cardiol** **2015**;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043.

106. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, Oreto G, Zijlstra F, Valgimigli M. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. **Eur Heart J** **2015**;36(20):1242-51. doi: 10.1093/eurheartj/ehv038.
107. Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M, Biscaglia S, Valgimigli M. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. **Catheter Cardiovasc Interv** **2015**;86(1):E19-27. doi: 10.1002/ccd.25822.
108. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. **Lancet** **2015**;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6.
109. Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). **Am J Cardiol** **2015**;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043.
110. De Servi S, Cavallini C, Leonardi S, Ferlini M. Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. **Int J Cardiol** **2015**;181C:443-445. doi: 10.1016/j.ijcard.2014.11.131.
111. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, Caporale R, Abrignani MG, Lupi A, Rakar S, Gulizia MM, Bovenzi FM, De Servi S; on behalf of the EYESHOT investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. **Eur Heart J Acute Cardiovasc Care** **2015**;4(5):441-52. doi: 10.1177/2048872614560505.

112. Crimi G, Ferlini M, Gallo F, Sormani MP, Raineri C, Bramucci E, De Ferrari GM, Pica S, Marinoni B, Repetto A, Raisaro A, Leonardi S, Rubartelli P, Visconti LO, Ferrario M. Remote ischemic postconditioning as a strategy to reduce acute kidney injury during primary PCI: A post-hoc analysis of a randomized trial. **Int J Cardiol** **2014**;177(2):500-2. doi: 10.1016/j.ijcard.2014.08.080.
113. Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). **Am J Cardiol** **2014**; 114(5):665-73. doi: 10.1016/j.amjcard.2014.05.054.
114. Marino M, Rizzotti D, Leonardi S. Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). **Curr Cardiol Rep** **2014**;16(6):493. doi: 10.1007/s11886-014-0493-4.
115. Iannopollo G, Camporotondo R, De Ferrari GM, Leonardi S. Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. **Ther Clin Risk Manag** **2014**;10:321-9. doi: 10.2147/TCRM.S39216.
116. Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV, Mehran R, Valgimigli M. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. **Eur Heart J** **2014 Oct 1**; 35(37):2524-9. doi: 10.1093/eurheartj/ehu161.
117. Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). **Am J Cardiol** **2014**;113(6):936-44. doi: 10.1016/j.amjcard.2013.11.052.
118. Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, Ferlini M, Marinoni B, Repetto A, Romeo M, Rosti V, Massa M, Raisaro A, Leonardi S, Rubartelli P, Oltrona Visconti L, Ferrario M. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. **JACC Cardiovasc Interv** **2013**;6(10):1055-63. doi: 10.1016/j.jcin.2013.05.011.

119. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. **Lancet** **2013**; 382(9909):1981-92. doi: 10.1016/S0140-6736(13)61615-3.
120. Tricoci P, Leonardi S, White J, White HD, Armstrong PW, Montalescot G, Giugliano RP, Gibson CM, Van de Werf F, Califf RM, Harrington RA, Braunwald E, Mahaffey KW, Newby LK. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. **J Am Coll Cardiol** **2013 Jul 16**;62(3):242-51. doi: 10.1016/j.jacc.2013.04.043.
121. Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, Moliterno D, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA Mahaffey KW. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA-CER) trial. **Eur Heart J** **2013 Jun**;34(23):1723-31. doi: 10.1093/eurheartj/eh104.
122. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. **N Engl J Med** **2013**;368(14):1303-13. doi: 10.1056/NEJMo1300815.
123. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Todd M, Bhatt DL, Stone GW, Lincoff AM, Dauerman HL, Gibson CM, White HD, Parikh KH, Gruberg L, Herrmann HC, McLaurin BT, Goodman SG, Mahaffey KW. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. **Coron Artery Dis** **2013**; 24(4):321-7. doi: 10.1097/MCA.0b013e32835f2fbd.
124. Leonardi S, Truffa AA, Neely ML, Tricoci P, White HD, Gibson CM, Wilson M, Stone GW, Harrington RA, Bhatt DL, Mahaffey KW. A novel approach to systematically implement the universal

- definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. **Heart** **2013 Sep**;99(17):1282-7. doi: 10.1136/heartjnl-2012-303103.
125. Leonardi S, Armstrong PW, Schulte PJ, Ohman EM, Newby LK. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. **Eur Heart J** **2013 Mar**;34(12):894-902d. doi: 10.1093/eurheartj/ehf003.
126. Leonardi S, Thomas L, Neely ML, Tricoci P, Lopes RD, White HD, Armstrong PW, Giugliano RP, Antman EM, Califf RM, Newby LK, Mahaffey KW. Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention Related-Myocardial Infarction. **J Am Coll Cardiol** **2012 Dec 4**;60(22):2296-2304. doi: 10.1016/j.jacc.2012.09.005.
127. Leonardi S, Chen AY, Gharacholou SM, Wang TY, de Lemos JA, Saucedo JF, Peterson ED, Roe MT. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. **Am Heart J** **2012**;164(4):502-508. doi: 10.1016/j.ahj.2012.07.005.
128. Valgimigli M, Leonardi S. Peri-procedural myocardial infarction and troponin: a quick journey through the land of confusion. **Heart** **2012**;98(19):1400-1401. doi: 10.1136/heartjnl-2012-302612.
129. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; on behalf of the INNOVATE-PCI Investigators. A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial. **Circ Cardiovasc Interv** **2012**;5:336-346. doi: 10.1161/CIRCINTERVENTIONS.111.964197.
130. Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. **Am Heart J** **2012**;163:768-776. doi: 10.1016/j.ahj.2012.02.018.
131. Leonardi S, Tricoci P, Mahaffey KW. Promises of PAR-1 Inhibition in Acute Coronary Syndrome. **Curr Cardiol Rep** **2012**;14:32-39. doi: 10.1007/s11886-011-0232-z.

132. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; the TRACER Investigators. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. **N Engl J Med** **2012 Jan 5**;366:20-33. doi: 10.1056/NEJMoa1109719.
133. De Ferrari GM, Leonardi S, Baduena L, Chieffo E, Lesce A, Repetto A, Previtali M. Patients with acute coronary syndrome and non-obstructive coronary disease in the real world are markedly undertreated. **J Cardiovasc Med (Hagerstown)** **2011**;12:700-708. doi: 10.2459/JCM.0b013e328348e575.
134. Leonardi S, Tricoci P, Becker RC. Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Therapeutic Potential of Vorapaxar and E-5555. **Drugs** **2010**;70:1771-83. doi: 10.2165/11538060-000000000-00000.
135. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y₁₂-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). **Am Heart J** **2010 Jul**;160:65-72. doi: 10.1016/j.ahj.2010.04.008.
136. Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. **Eur Heart J** **2009**;30:2003-2010. doi: 10.1093/eurheartj/ehp152.
137. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S. Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice. **JAMA** **2005**;294:2975-2980. DOI: 10.1001/jama.294.23.2975.

Pubblicazioni come Investigator (non-author contributions) (19)

1. Iorio A, Lombardi CM, Specchia C, Merlo M, Nuzzi V, Ferraro I, Peveri G, Oriecua C, Pozzi A, Inciardi RM, Carubelli V, Bellasi A, Canale C, Camporotondo R, Catagnano F, Vecchia LD, Giovinazzo S, Maccagni G, Mapelli M, Margonato D, Monzo L, Provenzale G, Sarullo F, Tomasoni D, Ameri P, Gnecci M, Leonardi S, Agostoni P, Carugo S, Danzi GB, Guazzi M, La Rovere MT, Mortara A, Piepoli M, Porto I, Volterrani M, Sinagra G, Senni M, Metra M. Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study). **Am J Cardiol.** 2022 Jan 18:S0002-9149(21)01204-2. doi: 10.1016/j.amjcard.2021.11.054.
2. Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. **Cardiovasc Res.** 2021 Dec 2:cvab343. doi: 10.1093/cvr/cvab343.
3. Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. **Eur Heart J.** 2021 Nov 16:ehab696. doi: 10.1093/eurheartj/ehab696.
4. Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. **Eur Heart J.** 2021 Nov 16:ehab697. doi: 10.1093/eurheartj/ehab697.
5. Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. **Cardiovasc Res.** 2021 Dec 2:cvab342. doi: 10.1093/cvr/cvab342.
6. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. **J Am Coll Cardiol.** 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102

7. Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B; SOLOIST-WHF committees and investigators. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. **Ann Intern Med.** 2021 Aug;174(8):1065-1072. doi: 10.7326/M21-0651.
8. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. **Diabetes Care.** 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842
9. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. **N Engl J Med.** 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183.
10. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. **N Engl J Med.** 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797.
11. D'Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, Ariza-Solé A, Liebetau C, Manzano-Fernández S, Quadri G, Kinnaird T, Campo G, Simao Henriques JP, Hughes JM, Dominguez-Rodriguez A, Aldinucci M, Morbiducci U, Patti G, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM; PRAISE study group. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. **Lancet.** 2021 Jan 16;397(10270):199-207. doi: 10.1016/S0140-6736(20)32519-8.

12. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. **Diabetes Care**. 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842.
13. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercurio G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C; Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. **Eur Heart J**. 2020 Jun 7;41(22):2083-2088. doi: 10.1093/eurheartj/ehaa409.
14. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. **Lancet Diabetes Endocrinol**. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: *Lancet Diabetes Endocrinol*. 2019 Jul 8;.: *Lancet Diabetes Endocrinol*. 2019 Sep;7(9):e21
15. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. **N Engl J Med** 2017;377(13):1228-1239.
16. Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. **J Am Heart Assoc** 2016;5(9). doi: 10.1161/JAHA.116.003421.
17. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI

- Investigators. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. **Lancet** **2016**;387(10016):349-56.
18. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. **Lancet Neurol** **2012**;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8.
19. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Ghalibaf M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. **N Engl J Med** **2011**;365(11):981-92.

Capitoli di Libro

1. Leonardi S, Modine T, Windecker S. The heart team. ESC Textbook of Intensive and Acute Cardiovascular Care (IACC). Oxford University Press. February 2021, DOI: 10.1093/med/9780198849346.003.0004
2. Leonardi S, Becker RC. PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis. Gresele et al. (eds.), Antiplatelet Agents, Handbook of Experimental Pharmacology. Springer-Verlag Berlin Heidelberg 2012
3. Leonardi S, Tricoci P, Becker RC. Protease-Activated Receptor-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome. Serebruany VL, Atar D (eds): Antiplatelet Therapy in ACS and A-Fib. Adv Cardiol. Basel, Karger, 2012, vol 47, pp 87–99.
4. Hafley GE, Leonardi S, Pieper KS. Phase III and IV Clinical Trials. Understanding Clinical Research. McGraw-Hill's 2012.
5. De Ferrari GM, Leonardi S: Farmaci antiaritmici di classe II: farmacocinetica, farmacodinamica e uso clinico. Trattato Italiano di Elettrofisiologia ed Elettrostimolazione Cardiaca AIAC. Volume 3, Capitolo159 (Centro Scientifico Editore–Torino) 2009, pp.1384-1389.

6. De Ferrari GM, Leonardi S: Farmaci antiaritmici di classe III: farmacocinetica, farmacodinamica e uso clinico. Trattato Italiano di Elettrofisiologia ed Elettrostimolazione Cardiaca AIAC. Volume 3, Capitolo 160 (Centro Scientifico Editore–Torino) 2009, pp.1390-1398.

Premi e Riconoscimenti

Best Moderated Poster Award 2015, European Society of Cardiology Congress, London, 31 August 2015. Prediction models in clinical practice. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: the CHAMPION experience.

Finalist – Northwestern Cardiovascular Young Investigators’ Forum. September 22-25, 2011. Program Chair: Dr Robert Bonow. Chicago, IL. Research Title: "Are All Myocardial Infarctions the Same? A Novel Approach With Emphasis on Comparing the Prognosis of Spontaneous and Percutaneous Coronary Intervention Related Myocardial Infarction".

Reviewer Role in Clinical Event Committee (CEC)

Sono stato reviewer dei seguenti studi clinici:

- CHAMPION PLATFORM – *N Engl J Med* 2009; 361(24):2330-41.
- CHAMPION PCI – *N Engl J Med* 2009; 361(24):2318-29.
- APPRAISE-2 – *N Engl J Med* 2011;365(8):699-708.
- ARISTOTLE – *N Engl J Med*.2011 365(11):981-92.
- TRA-CER – *N Engl J Med* 2012;366:20-33.

Sono stato CEC co-chair del CHAMPION PHOENIX trial (*N Engl J Med* 2013) e del MATRIX trial (*N Eng J Med* 2015) e MASTERDAPT.

Ruolo come Editor e Peer-Reviewer

Editorial board member: *European Heart Journal: Acute Cardiovascular Care* (EHJ:ACVC), official journal of the Acute Cardiovascular Care Association; *American Heart Journal*

Sono **reviewer** di diverse e prestigiose riviste peer-reviewed tra cui il *New England Journal of Medicine*, *Circulation*, *European Heart Journal*, *Circulation Cardiovascular Intervention*, *American Heart Journal*, *American Journal of Cardiology*, *Journal of Cardiovascular Medicine*, *Drugs*.

Il sottoscritto, infine, esprime il proprio consenso affinché i dati personali forniti possano essere trattati, nel rispetto del D. Lgs. n.196/2003 e dell'art. 13 del Regolamento (UE) 2016/679, per gli adempimenti connessi alla procedura.

Pavia, Gennaio 2022

A handwritten signature in dark ink, appearing to read "Sergio Lenardi". The signature is written in a cursive style with a large initial 'S'.